Introduction
The trade-off question at hand is whether Owkin should prioritize expanding its AI model capabilities or focus on improving interpretability for its existing models. This scenario involves balancing innovation with transparency in the field of AI-driven healthcare solutions. I'll address this complex decision by analyzing the product context, stakeholder impacts, and potential outcomes.
I'd like to outline my approach to ensure we're aligned on the key areas I'll cover in my analysis.
Step 1
Clarifying Questions (3 minutes)
Why it matters: Helps tailor the solution to specific healthcare needs Expected answer: Oncology, drug discovery, and clinical trial optimization Impact on approach: Would influence which capabilities to prioritize
Why it matters: Determines the urgency of improving interpretability Expected answer: Highly critical, as partners require transparency for regulatory compliance Impact on approach: Would lean towards prioritizing interpretability if it's a major revenue driver
Why it matters: Different user groups may have varying needs for interpretability vs. capabilities Expected answer: 60% researchers, 40% clinicians Impact on approach: Would influence the focus on either advanced capabilities or user-friendly interpretability
Why it matters: Determines the resources and timeline required for improving interpretability Expected answer: Moderately challenging but achievable with current expertise Impact on approach: Would influence the allocation of technical resources and development timeline
Why it matters: Helps understand the current prioritization and potential for reallocation Expected answer: 70% on capabilities, 30% on interpretability Impact on approach: Would inform the feasibility of shifting focus without significant restructuring
Practice similar questions
Subscribe to access the full answer